Translate page

Highlights from ASH 2018 Annual Meeting:

At ASH in San Diego, the CML education session was entitled 'With Great Success Comes Great Responsibility'. Professors Jane Apperley, Timothy Hughes and Charles Craddock gave respective presentations on the treatment of CML with TKIs, molecular monitoring to aid clinical decision making and the role of transplantation in managing CML. Below are interviews from the presenters on their perspectives on the session. 

These summaries are brought to you with support from Bristol Myers Squibb.

In addition, we are pleased to be able to offer you a complete scientific summary of the education session on CML. This also contains a summary of relevant abstracts on; TFR failure, resistance and new drug development.

Download the scientific summary report here

Summaries of the ASH CML Education Session

The Argument for Using Imatinib in CML

Professor Jane Apperley
Imperial College London, London, UK

Jane Apperley described the outcome of newly diagnosed patients newly treated with first or second generation TKIs. She discussed balancing the desire to achieve the deep molecular responses that permit trials of TKI discontinuation with the potential adverse effects of earlier use of the more potent TKI's, and provided pragmatic advice regarding treatment decisions.  

Importance of Molecular Monitoring in CML: How Deep, How Often, and How Should it Influence Therapy?

Professor Timothy Hughes
Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

Tim Hughes explored the appropriate time-dependent molecular targets for CML patients on TKI and the reasons why those targets differ, especially when considering treatment discontination. He also discussed the facts that influence the choice of TKI when molecular responses are not optimal and highlighted the critical role of molecular monitoring in managaging treatment-free remission.   

We Do Still Transplant CML, Don't We?

Professor Charles Craddock
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK

Charles Craddock summarised the results of alloSCT in all phases of CML and discussed factors affecting decision-making now that increased donor availability and reduced intensity conditioning regimes have increased the number of transplant eligible patients. As disease relapse remains a major cause of treatment failure he focused on emerging peri- and post-transplant strategies to improve the outcome.   

Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany) 

  • Scientific workshops on imaging and genome editing
  • Novel strategies with new pathways complementing existing TKI therapies
  • Skeleton muscle toxicities induced by TKI's
  • Possible relationship between dopamin receptors and leukemic stem cell receptors
  • Debate on eradicating remaining stem cells
  • Innovative new technologies for monitoring

 {rscomments off}

Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)

  • Update on new studies including TIGER and SPIRIT II 
  • Long-term outcomes from clinical studies on treatment-discontinuation
  • Various aspects on treatment-free-remission such as predictors of success, biomarkers, gene analysis, use of digital PCR, pregnancy
  • New modalities and tools of monitoring patients 
  • Biology of CML and the role of microenvironment and molecular abnormalities

 {rscomments off}

Highlights from the John Goldman Conference on CML 2017:
CML experts give their personal perspectives

In Spanish:
Perspectivas sobre nuevas estudios clínicos y cómo se transfieren al mundo real - especialmente en países en vía de desarollo
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina

  • Actualización del estudio CML-IV: Seguridad y eficacia de imatinib durante 10 años
  • Actualización del estudio PACE: Uso de ponatinib en segunda y tercera línea
  • Varios estudios clínicos del discontinuación del tratamiento y qué aspectos deberían considerarse en la aplicación práctica
  • Tratamiento de la población pediátrica y el uso de nuevas tecnologías para el monitoreo molecular